# A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

> **NCT03310021** · PHASE2 · COMPLETED · sponsor: **Portola Pharmaceuticals** · enrollment: 108 (actual)

## Conditions studied

- Bleeding

## Interventions

- **BIOLOGICAL:** Andexanet alfa
- **DRUG:** Apixaban
- **DRUG:** Rivaroxaban
- **DRUG:** Edoxaban
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03310021
- **Lead sponsor:** Portola Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-28
- **Primary completion:** 2019-08-13
- **Final completion:** 2019-08-13
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2023-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03310021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03310021, "A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03310021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*